Reply
- PMID: 32936518
- DOI: 10.1002/art.41522
Reply
Comment on
-
2020 American College of Rheumatology Guideline for the Management of Gout.Arthritis Rheumatol. 2020 Jun;72(6):879-895. doi: 10.1002/art.41247. Epub 2020 May 11. Arthritis Rheumatol. 2020. PMID: 32390306
-
Treat-to-Target in Gout Management? Comment on the Article by FitzGerald et al.Arthritis Rheumatol. 2021 Mar;73(3):543-544. doi: 10.1002/art.41523. Epub 2021 Jan 27. Arthritis Rheumatol. 2021. PMID: 32951325 No abstract available.
References
-
- Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 2018;392:1403-12.
-
- Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, et al. Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 2017;69:2386-95.
-
- Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306:711-20.
-
- Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical